Globe Life reported FY 2025 net income of USD 1.16 billion (+8.5%) and net operating income of USD 1.20 billion (+8.1%), with diluted EPS of USD 14.07 (+17.8%) and diluted net operating EPS of USD 14.52 (+17.4%). Total premium rose to USD 4.9 billion (+5.0%), including life premium of USD 3.4 billion (+3.0%) and health premium of USD 1.5 billion (+9.0%). Total net sales increased to USD 948 million (+12.9%), driven by health net sales of USD 333 million (+36.0%) and life net sales of USD 615 million (+3.0%). Book value per share was USD 74.17 (+18.7%), while book value per share excluding AOCI was USD 96.16 (+11.3%). By segment, life underwriting margin was USD 1.51 billion (+11.6%) and health underwriting margin was USD 390.1 million (+4.8%); excess investment income was USD 138.4 million (-15.8%), with excess investment income per diluted share of USD 1.68 (-8.2%). Globe Life said life underwriting margin benefited from assumption updates, including a life remeasurement gain of USD 130.9 million, and noted health premium growth was supported by Medicare supplement sales and rate increases, alongside a consumer shift from Medicare Advantage to Medicare supplement plans. The company repurchased 5.4 million shares for USD 685.2 million in FY 2025 (average price USD 126.41) and reported a FY 2025 ROE of 20.9% and net operating ROE excluding AOCI of 16.0%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Globe Life Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000320335-26-000090), on February 25, 2026, and is solely responsible for the information contained therein.
Comments